INO Inovio Pharmaceuticals, Inc.: Rasio Kapitalisasi Pasar marang Nilai Buku

This chart of exchange quotes on the GURU.Markets platform demonstrates the price action of Inovio Pharmaceuticals (INO), whose metric stands at 17.76. Inovio Pharmaceuticals (INO) is advancing the field of genetic medicine by implementing direct delivery of biomaterials for the therapy of cancer and viruses. The business relies on a closed model utilizing unique CELLECTRA injectors, while the team led by Jacqueline Shea is finalizing preparations for the first commercial sales.

Investors are assessing the resilience of Inovio Pharmaceuticals (INO) through the price-to-book ratio, which determines the market premium over real capital. When analyzing changes in the revaluation of balance sheet capital, it is critical to consider that geopolitical risks and biomaterial supply chain disruptions could compress this premium, turning a local decline into a signal of either fundamental undervaluation or a systemic crisis.